In a historic milestone for respiratory medicine, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Jointly developed by Regeneron Pharmaceuticals and Sanofi, Dupixent becomes the first-ever targeted biologic medicine authorized in the United States for COPD.
Chronic obstructive pulmonary disease is the fourth leading cause of death worldwide, characterized by progressive lung airflow limitation and recurrent, debilitating exacerbations. Despite widespread use of standard inhaled triple therapies—combining corticosteroids, long-acting beta-agonists, and muscarinic antagonists—approximately 300,000 Americans with COPD continue to suffer from persistent breathlessness and hospitalizations driven by underlying type 2 airway inflammation.
Clinical Efficacy Across Landmark BOREAS and NOTUS Trials
The FDA's regulatory clearance was underpinned by conclusive data from two pivotal Phase 3 trials, BOREAS and NOTUS. In both multinational studies, patients receiving subcutaneous injections of Dupixent every two weeks experienced a statistically significant 30% to 34% reduction in annualized moderate-to-severe exacerbations compared to placebo, alongside sustained improvements in lung function (FEV1) and health-related quality of life.
Dupixent functions as a fully human monoclonal antibody that specifically inhibits the signaling pathways of interleukin-4 (IL-4) and interleukin-13 (IL-13), two primary cytokines driving type 2 inflammation. By intercepting these key immunological drivers, the therapy tackles the root inflammatory cascade rather than merely offering symptomatic bronchodilation.
“This approval represents a historic breakthrough for hundreds of thousands of COPD patients who have lived for decades without a targeted biologic medicine to manage their debilitating lung disease.”
A Paradigm Shift in Managing Type 2 Airway Inflammation
The landmark indication substantially broadens Dupixent's therapeutic franchise, which already encompasses major approvals for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Wall Street analysts forecast that the COPD label will add billions of dollars in peak annual sales for both pharmaceutical partners, while reshaping standard pulmonology treatment guidelines.
Regeneron and Sanofi announced that Dupixent will be made available immediately to eligible U.S. patients through prescription specialty pharmacies. Pulmonary specialists nationwide hailed the regulatory decision, emphasizing that identifying elevated blood eosinophil counts will now allow clinicians to deliver precision medicine to a long-underserved patient demographic.
Comments (0)
Log in to join the discussion.